As shown in Figure 5, patients in the low-risk group mainly involved in the ERBB signaling pathway, MAPK signaling pathway, MTOR signaling pathway, WNT signaling pathway, insulin signaling pathway, and renal cell carcinoma pathway, etc. The gene discussed is MTOR; the disease is renal cell carcinoma.